Evidence map›Paper›PMID 39268398›Full record

ArticlePulmonary circulation2024

Scoping review of post-TB pulmonary vascular disease: Proceedings from the 2nd International Post-Tuberculosis Symposium.

Elizabeth H Louw, Jennifer A Van Heerden, Ismail S Kalla, Gerald J Maarman, Zoliswa Nxumalo, Friedrich Thienemann, Moises A Huaman, Matthew Magee, Brian A Allwood

Abstract readScoping Review
In one paragraph

Article in Pulmonary circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Post-tuberculosis lung disease.Breathe (Sheffield, England) · 2026
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elizabeth H LouwDepartment of Medicine, Division of Pulmonology Stellenbosch University & Tygerberg Hospital Cape Town South Africa.ORCID 0000-0003-4385-2249
Jennifer A Van HeerdenNuffield Department of Surgical Sciences, Medical Sciences Division University of Oxford Oxford UK.ORCID 0000-0003-0813-7645
Ismail S KallaDepartment of Medicine, Division of Pulmonology University of Witwatersrand Johannesburg South Africa.ORCID 0000-0001-9131-7123
Gerald J MaarmanDepartment of Biomedical Sciences, Centre for Cardio-Metabolic Research in Africa (CARMA), Division of Medical Physiology, Faculty of Medicine & Health Sciences Stellenbosch University Cape Town South Africa.ORCID 0000-0003-3336-5594
Zoliswa NxumaloDepartment of Medicine Stellenbosch University & Tygerberg Hospital Cape Town South Africa.ORCID 0009-0004-4859-4810
Friedrich ThienemannDepartment of Medicine and Cape Heart Institute, General Medicine & Global Health Research Unit, Faculty of Health Science University of Cape Town Cape Town South Africa.ORCID 0000-0002-4801-2030
Moises A HuamanHubert Department of Global Health, Rollins School of Public Health Emory University Atlanta Georgia USA.ORCID 0000-0002-6839-5809
Matthew MageeInfectious Diseases Research Unit, CCTST K Scholars Program University of Cincinnati College of Medicine Cincinnati Ohio USA.ORCID 0000-0003-1817-1564
Brian A AllwoodDepartment of Medicine, Division of Pulmonology Stellenbosch University & Tygerberg Hospital Cape Town South Africa.ORCID 0000-0003-0421-2978

Funding

Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Jeffrey M Collins · 2022 to 2026
$5.8M
6 · The paper itself

Abstract

Tuberculosis (TB) may cause significant long-term cardiorespiratory complications, of which pulmonary vascular disease is most under-recognized. TB is rarely listed as a cause of pulmonary hypertension (PH) in most PH guidelines, yet PH may develop at various stages in the time course of TB, from active infection through to the post-TB period. Predisposing risk factors for the development of PH are likely multifactorial, involving active TB disease and post-TB lung disease (PTLD), host-related and environment-related factors. Moreover, post-TB PH should likely be classified in Group 3 PH, with the pathogenesis similarly complex and multifactorial as other Group 3 PH causes. Identifying risk factors that predispose to post-TB PH may aid in developing risk stratification criteria for early identification and referral for confirmatory diagnostic tests. Given that universal screening for PH in TB survivors may be impractical and unfeasible, a targeted screening approach for high-risk individuals would be sensible. In this scoping review of post-TB PH, resulting from the proceedings of the 2nd International Post-Tuberculosis Symposium, we aim to describe the epidemiology, risk factors, and pathophysiology of post-TB PH. We emphasize diagnosing PH with an alternative set of diagnostic guidelines in resource-constrained settings where right heart catheterization may not be feasible. Research to describe the burden and distribution of post-TB PH should be prioritized as there is a current gap in knowledge regarding the prevalence and incidence of post-TB PH among persons with TB.

Indexed as

chronic lung diseasepost‐tuberculosis lung diseasepulmonary hypertension

Identifiers

PMID39268398
PMCPMC11391472

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.